In 2018, the average cost of developing a new drug and bringing it to market topped $2.1 billion—up $362 million from 2017 according to a Deloitte survey. One of the challenges pharmaceutical companies face is attrition and non-adherence during patient trials. Traditional methods, focused on call centers, complex documentation and feedback limitations, lack the ability to collect enough real-world evidence to get the full patient experience picture.

In this episode, Justin Mardjuki and Greg Kefer talk about the challenges the industry faces and how chatbots can be a viable option to improve the research process, during both trial and in-market phases across large patient populations.